New uterine sampler aims to make cancer detection less painful

NCT ID NCT04258449

Recruiting now Diagnosis Sponsor: McGill University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new device called DOvEEgene Fleur for collecting cells from inside the uterus to detect cancers of the endometrium, tubes, and ovaries. The goal is to see if it is less painful and easier to use than the current brush, while still collecting enough cells for accurate testing. Forty women with suspected or confirmed gynecological cancer will try the device before surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DOvEEgene Fleur endometrial sampling device
What this could lead to: If successful, this could lead to a more comfortable and effective way to collect samples for early detection of uterine and ovarian cancers.
What could go wrong: This is a small, early-stage study with only 40 participants, so results may not apply to everyone. The device is new and its performance compared to standard tools is still being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrium neoplasm fallopian tube cancer female reproductive system disorder ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

WOMEN WITH SUSPECTED OR CONFIRMED GYNECOLOGICAL DISEASE

Contacts and locations

Locations

Royal Victoria Hospital (Glen Site)
RECRUITING

Montreal, Quebec, H4A 3J1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.